baber/WOPTO huggingface dataset:
Patent NZ-535109-A (NZ)
Title: Pyrimidine derivatives
Inventor: BAENTELI ROLF
IPC: A61P5/14
Filed: 2003-03-14
Abstract: Disclosed herein is a compound of formula (I) and the use of said compound in free form or in pharmaceutically acceptable salt form, in the preparation of a medicament for use in the treatment or prevention of a disease in which ZAP-70, FAK and/or Syk tyrosine kinase activation plays a role or is implicated.
Patent NZ-536446-A (NZ)
Title: Floorboards and flooring systems for patterned floating flooring
Inventor: PERVAN DARKO
IPC: E04F15/02
Filed: 2003-04-22
Abstract: Floorboards are disclosed with a format corresponding to a traditional parquet block for laying of mechanically joined floating flooring. Further disclosed is flooring systems and methods for manufacturing and installation of floorings comprising such floorboards.
Patent NZ-539862-A (NZ)
Title: Nutritional formulations containing synbiotic substances
Inventor: KAUP SUSAN MARIE
IPC: A23L1/30
Filed: 2003-10-08
Abstract: A nutritional composition comprises oligofructose, sialyllactose and probiotic bacteria wherein the probiotic bacteria is Lactobacillus acidophilus and Bifidobacterium lactis. The composition can be used in the manufacture of a medicament for eradicating pathogenic organisms in the gastrointestinal tract.
Patent NZ-547216-A (NZ)
Title: Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
Inventor: GREENSMITH LINDA
IPC: A61K31/4545
Filed: 2004-10-25
Abstract: Disclosed is the use of a chemical substance selected from N-[2-hydroxy-3-(1-piperindinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, an optionally active enantiomer or mixture of enantiomers thereof and a pharmaceutically acceptable salt of the optically active enantiomers or mixture of enantiomers thereof in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases of the central nervous system.
Patent NZ-552706-A (NZ)
Title: Use of aspartate for regulating glucose levels in blood
Inventor: HAGEMAN ROBERT JOHAN JOSEPH
IPC: A23L13/40
Filed: 2005-07-18
Abstract: Disclosed is a liquid nutritional or liquid pharmaceutical composition; said composition containing a protein fraction comprising a first and a second source of aspartate equivalents, wherein said first source is a protein, said protein fraction comprising at least 10.8 wt% of aspartate equivalents, based on the weight of the protein fraction, wherein at least part is provided by an aspartate source containing at least 12.0 wt% aspartate equivalents, based on the weight of the aspartate source; and wherein said composition contains a minimum amount of 10 en% protein. The composition may be used to treat insulin resistance, glucose intolerance and/or hyperglycemia in a mammal.
Patent NZ-555625-A (NZ)
Title: Lateral trench field-effect transistors in wide bandgap semiconductor materials, methods of making, and intergrated circuits incorperating the transistors
Inventor: SANKIN IGOR
IPC: H01L21/332
Filed: 2005-11-30
Abstract: A junction field-effect transistor is disclosed. The transistor includes: a substrate (1) having opposed first and second major surfaces; a drain layer (2) of an n-type semiconductor material on the first major surface of the substrate; a drift layer (3) of an n-type semiconductor material on and non-coextensive with the drain layer such that portions of the drain layer are exposed, the drift layer having a lower conductivity than the drain layer; a channel region of an n-type semiconductor material on the drift layer; a source region of an n-type semiconductor material on the channel region, the material of the source region having a higher conductivity than that of the channel region; a gate region (7) of a p-type semiconductor material on the drift layer adjacent the one or more raised regions and forming a rectifying junction with n-type material of the drift layer and the channel region(s); and ohmic contacts (9) on the gate and source regions and on exposed portions of the drain layer.
Patent NZ-560712-A (NZ)
Title: (3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders
Inventor: SUN LIJUN
IPC: A61K31/42
Filed: 2006-02-16
Abstract: Disclosed are isoxazole compounds represented by formula (V), wherein one of Ri or Rj is H and the other is a 3,4,5-trisubstituted phenyl group, and R2 is an optionally substituted phenyl or heteroaromatic ring, and the remaining substituents are as defined in the specification. The compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.
Patent NZ-565304-A (NZ)
Title: A financing method and system
Inventor: DUNCAN ANDREW GARETH
Filed: 2006-07-19
Abstract: A computer system for determining the viability of purchasing an energy efficient product is disclosed. The system includes a processor arranged to retrieve a rate value for a loan, retrieve a cost value for the product, request approval from a territorial authority that the authority agrees to collect a levy associated with payment of the loan, calculate an energy cost saving value associated with the product, and, upon receipt of approval from the territorial authority, calculate the financial viability of purchasing the product by determining if the energy cost saving value is equal to or more than a total cost amount. The total cost amount includes payment of the loan for the cost value at the rate value retrieved.
Patent NZ-574958-A (NZ)
Title: Capsule for the preparation of a beverage
Inventor: OZANNE MATTHIEU
IPC: A47J31/40
Filed: 2007-08-23
Abstract: A capsule for brewing food fragments in a beverage machine is disclosed. The capsule comprises an enclosure (20) containing food fragments, a filtering means (22), and an overflow wall (3). The filtering means (22) delimits at least one filtering side of the enclosure and is integral with the overflow wall (3). The overflow wall (3) is positioned in a path of a brewed liquid after the filtering means (22) and comprises at least one overflow aperture (25).
Patent NZ-576654-A (NZ)
Title: Injection device with retractable needle, released by a trigger
Inventor: BURNELL ROSEMARY LOUISE
IPC: A61M5/20
Filed: 2007-11-13
Abstract: Disclosed is an injection syringe device with a retractable needle with a trigger and releasable lock mechanism for improved safety for users and patients by reducing accidental discharges of the needle. The device contains a housing with a syringe needle that in a retracted position and contained within the housing or an extended position where the needle is outside the housing. A spring drives the syringe and needle from the retracted to the extended position through an exit aperture. A trigger when in a rest position, retains the compressed spring, then when the trigger is moved to an active position, the spring drive is released, which extends the needle. A releasable locking mechanism is movable from a first position, in which the trigger is prevented from moving into its active position, to a second position, in which the trigger can be moved to its active position. The trigger has a separate activation surface, and while pressure is applied to the activation surface, the releasable locking mechanism is moved from its first to its second position and the trigger can be moved from its rest position to its active position.
Patent NZ-578633-A (NZ)
Title: Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of b-chronic lymphocytic leukaemia
Inventor: MONTERO CASIMIRO JOSE ENRIQUE
IPC: A61P35/02
Filed: 2007-12-24
Abstract: Disclosed is the use of a pharmaceutical composition comprising a humanized monoclonal antibody recognizing the leukocyte differentiation antigen C06 able to induce apoptosis in tumor cells, and an appropriate excipient in the manufacture of a medicament for the diagnosis and/or treatment of B-Cell Chronic Lymphocytic Leukemia. Further disclosed is a humanized anti-C06 monoclonal antibody when used for the in-vitro diagnosis of the B-Cell Chronic Lymphocytic Leukemia.
Patent NZ-579305-A (NZ)
Title: Diagnosis of collagen ix destruction
Inventor: HEINEGARD DICK
IPC: C07K14/78
Filed: 2008-02-29
Abstract: Provided is a method of detecting or monitoring a human disorder affecting connective tissues, comprising determining the levels of cleaved protein fragments of the alpha-1 chain of collagen IX in a blood sample or a synovial fluid sample, wherein the fragments are selected from the group created by a cleavage at a site between glutamine-263 and threonine-264 in the CHELPARITPSQ263TTDERGPP271 of the human collagen IX alpha 1 chain in the NC4 domain. The cleavage neoepitopes PARITPSQ and TTDERGPP are also claimed, as well as antibodies binding the neoepitopes.
Patent NZ-579744-A (NZ)
Title: Adenine derivatives as TLR7 modulators
Inventor: ISOBE YOSHIAKI
IPC: A61K31/522
Filed: 2008-03-19
Abstract: Disclosed is an adenine compound of the formula (1) e.g. 6-Amino-2-(2-methoxyethoxy)-9-[4-(4-methylpiperazin-lylmethyl)benzyl]-7,9-dihydropurin-8-one wherein the variables are defined in the specification or a pharmaceutically acceptable salt thereof for therapy or prophylaxis of allergic diseases, viral diseases or cancer.
Patent NZ-584906-A (NZ)
Title: Gas burner for cooking applicances with air turbulating means to stir the primary air flow
Inventor: BIAGIOLI NICO
IPC: F23D14/06
Filed: 2008-12-04
Abstract: Disclosed is a gas burner particularly for household cooking appliances featuring a burner body with one more flame crowns. The burner has a horizontal or vertical gas supply conduit (1), a horizontal or vertical Venturi (4), and a nozzle (5) to inject the gas flow from the gas conduit into the Venturi pipe. It further has means to provide primary air flow which include a tubular conduit which is coaxial and placed outside the gas conduit, and an opening to allow the gas flow, placed between the nozzle and the inlet of the Venturi pipe. The coaxial conduit draws the respective air flow from a zone inside the body of the cooking appliance, and the opening allows the passage of the respective primary air flow sucked and coming from over the appliance top surface (12). In order to stir the primary air flow passing through the coaxial conduit, a plurality of radial wings (10A) is arranged, the wings being shaped either planar or helical, and being connected on the outer surface of the gas supply conduit.
Patent NZ-587753-A (NZ)
Title: Membrane with retina cells
Inventor: COFFEY PETER
IPC: A61K35/12
Filed: 2009-04-08
Abstract: A membrane that supports the growth of retinal pigmented epithelial cells and comprises a porous non-biodegradable support layer having a pore density of between 1 x 10^7 and 3 x 10^8 pores per square cm. The pore density allows for the desired permeability levels and allows vascularisation. The pores can have a size of between 0.2 micron and 0.5 micron in diameter and the support layer can have a side coated with a glycoprotein. The support layer can be a hydrophilic polymer of a polyester, a polyurethane, a polyuria-urethane, a polyamide, a polyether-ester, a polycarbonate, a polyacrylate, poly(tetrafluroethene), a polysiloxane, a polyelfin and polyoxymethylene. The membrane can be used for the treatment of age related macular degeneration.
Patent NZ-590714-A (NZ)
Title: Synergistic antimicrobial mixtures comprising zinc borate, ipbc and 2-(methoxycarbonylamino)benzimidazole
Inventor: GAGLANI KAMLESH
IPC: A01N47/12
Filed: 2009-06-05
Abstract: Disclosed herein is an antifungal composition, which comprises: 3-iodo-2-propynyl butyl carbamate, 2-(methoxycarbonylamino) benzimidazole, and zinc borate; in which the proportions of 3-iodo-2-propynyl butyl carbamate, 2-(methoxycarbonylamino) benzimidazole, and zinc borate (based on the total mass of 3-iodo-2-propynyl butyl carbamate, 2-(methoxycarbonylamino) benzimidazole, and zinc borate) in a triangular coordinate graph are within the interior of a triangle having as vertices 0 mass% 3-iodo-2-propynyl butyl carbamate, 72 mass% 2-(methoxycarbonylamino) benzimidazole, and 28 mass% zinc borate; 100 mass% 3-iodo-2-propynyl butyl carbamate, 0 mass% 2-(methoxycarbonylamino) benzimidazole, and 0 mass% zinc borate; and 47 mass% 3-iodo-2-propynyl butyl carbamate, 0 mass% 2-(methoxycarbonylamino) benzimidazole, and 53 mass% zinc borate.
Patent NZ-593448-A (NZ)
Title: Synthesis of fucosylated compounds
Inventor: HUFNER ERIC
IPC: A23L33/00
Filed: 2009-12-18
Abstract: A method for making a genetically modified cell that can produce fucosylated compounds. The method comprises the steps: (i) Transforming the cell to express a fucose kinase; (ii) Transforming the cell to express a fucose-1-phosphate guanylyltransferase; and (iii) Transforming the cell to express a fucosyltransferase. The fucosylated compound can be a fucosyllactose or lactodifucotetraose. The cell can be a microorganism from Escherichia, Klebsiella, Helicobacter, Bacillus, Lactobacillus, Streptococcus, Lactococcus, Pichia, Saccharomyces and Kluyveromyces.
Patent NZ-598781-A (NZ)
Title: Compounds as tyrosine kinase modulators
Inventor: GUO XIALING
IPC: A61K31/443
Filed: 2010-09-03
Abstract: Disclosed is a compound represented by Formula 1 e.g. [({ 5-[4-(2-fluoro-5-{ [(2-fluoro-5-methylphenyl)amino]carbonyl} phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl} carbonyl)amino]acetic acid wherein for the treatment of one of the diseases or conditions selected from the group consisting of colorectal cancer, lung cancer, hematological cancer, renal cancer, liver cancer, breast cancer, diabetic retinopathy, macular degeneration, age-related macular degeneration, retinopathy of prematurity, ocular angiogenesis, retinal edema, retinal ischemia, diabetic macular edema, cystoid macular edema, retinal vein occlusion, branch vein occlusion, preretinal neovascularization, laser-induced choroidal neovascularization, neovascularization associated with keratoplasty, glaucoma and ocular tumors, arthritis, restenosis, hepatic cirrhosis, atherosclerosis, psoriasis, diabetes mellitus, wound healing, inflammation, neurodegenerative diseases and immune disorders in the human being.
Patent NZ-599246-A (NZ)
Title: Pirfenidone therapy and inducers of cytochrome p450
Inventor: SZWARCBERG JAVIER
IPC: A61P43/00
Filed: 2010-12-03
Abstract: Disclosed is the use of pirfenidone in the manufacture of a medicament for treating a patient in need of pirfenidone therapy, wherein the treatment comprises avoiding or discontinuing concomitant use or co-administration of a strong inducer of cytochrome P450 1A2 (CYP1A2) to avoid reduced exposure to pirfenidone.
Patent NZ-605227-A (NZ)
Title: Method for feeding electrical power into a three-phase ac voltage system
Inventor: ADLOFF STEPHAN
IPC: H02J3/38
Filed: 2011-06-10
Abstract: Disclosed is an apparatus for feeding an unbalanced, three-phase current into a three-phase AC voltage system. At least one first inverter module (M1) produces a positive phase-sequence system for the current to be fed in and at least one second inverter module (M2) produces a negative phase-sequence system for the current to be fed in. The first inverter module (M1) and the second inverter module (M2) are coupled in such a manner that the positive phase-sequence system is superimposed with the negative phase-sequence system to form the current to be fed in.
Patent NZ-607423-A (NZ)
Title: Alkaline hydrolysis resistant adhesive
Inventor: CLINCH RICHARD
IPC: A47G27/04
Filed: 2011-06-24
Abstract: There is described herewith an alkaline hydrolysis resistant carpet adhesive comprising an n-butyl acrylate acrylic polymer.
Patent NZ-609580-A (NZ)
Title: Dynamic alarm sensitivity adjustment and auto-calibrating smoke detection
Inventor: GONZALES ERIC V
IPC: G08B29/26
Filed: 2010-10-01
Abstract: A microprocessor controlled hazardous condition detection system containing a sensor package (120), the sensor package (120) containing sensors exposed to the ambient environment. The system includes alarm means (130) coupled to the sensor package (120) through a microprocessor (110). The microprocessor (110) includes a memory storage device (150) containing a plurality of alarm thresholds stored therein. Each of the plurality of alarm thresholds is associated with a predetermined set of physical attributes. The microprocessor (110) receives physical attribute readings from the sensor package (120), and conditions the received readings by removing selected amounts of noise and attenuation therefrom. The microprocessor (110) accumulates the conditioned physical attribute readings, selects and employs an optimized alarm threshold from the plurality of stored alarm thresholds, based on a set of the accumulated physical attribute readings. Upon detecting physical attributes in the ambient environment greater than the physical attributes linked to the selected alarm threshold the microprocessor causes the alarm means (130) to generate an alarm.
Patent NZ-613250-A (NZ)
Title: Process for the treatment and the winemaking of grapes
Inventor: CATELLI CESARE
IPC: C12G1/02
Filed: 2012-01-13
Abstract: A grape treatment and wine making process comprises the steps of cleaning a first container by means of a fluid mixed with ozone; placing wine-making grapes in the first container in closed vats and/or buildings at controlled temperature; diffusing a fluid mixed with ozone at a first concentration within the closed vats or buildings at controlled temperature and diffusing a fluid mixed with ozone at a second concentration within the vats and/or buildings at controlled temperature. The first concentration is reduced to the second concentration following an increase of phenolic fractions within the wine-making grapes. The process further comprise cleaning a press by means of a fluid mixed with ozone; pressing the wine-making grapes with the press to produce must; cleaning a second container by means of a fluid mixed with ozone; placing the must in the second container to produce fermented must; cleaning a third container by means of a fluid mixed with ozone; placing the fermented must in the third container.
Patent NZ-614604-A (NZ)
Title: Customizable policy engine
Inventor: PRICE MICHAEL JOHN
IPC: G08B27/00
Filed: 2012-02-27
Abstract: Disclosed is a system for distributing warnings regarding an event. The system comprises a policy specification subsystem (1), a change detection subsystem (3), a policy execution subsystem (4) and an action processing subsystem (5). The policy specification subsystem (1) is configured for generating one or more machine readable policies. Each policy comprises at least one rule and at least one action associated with the at least one rule, wherein each rule includes a plurality of event parameters and an associated plurality of predetermined event parameter probabilities. The change detection subsystem (3) is configured for receiving and monitoring data from a sensor system (29). The data includes expected event parameter values and associated deviation metrics. The policy execution subsystem (4) is configured for executing the at least one rule and triggering the at least one action based on a comparison of the expected event parameter values and associated deviation metrics with the event parameters and the associated predetermined event parameter probabilities of the at least one rule, wherein the policy execution subsystem (4) initiates processing of the at least one rule after receiving instructions from the change detection subsystem (3). The change detection subsystem (3) sends instructions to the policy execution subsystem (4) upon detection of a predetermined change in at least one of the expected event parameter values. The action processing subsystem (5) is configured for generating an output for performing the at least one action triggered by the policy execution subsystem (4).
Patent NZ-615266-A (NZ)
Title: Keypad
Inventor: LAMBIE JOHN
IPC: G06F3/02
Filed: 2012-02-10
Abstract: 615266 The disclosure provides a keypad comprising at least consonant keys and vowel keys such that the vowel keys are arranged in a column between two edge columns of consonant keys, or in a row between two edge rows of consonant keys, wherein the consonant keys other than Z follow an alphabetic progression.
Patent NZ-623541-A (NZ)
Title: Human cgrp receptor binding proteins
Inventor: LU HSIENG SEN
IPC: C07K16/28
Filed: 2009-12-18
Abstract: Disclosed is an isolated antigen-binding protein that selectively inhibits the human calcitonin gene-related peptide (CGRP) receptor as compared with human AM1, AM2, and AMY1 receptors, said human CGRP receptor comprising a human CRLR polypeptide and a human RAMP1 polypeptide, wherein the antigen-binding protein comprises a light chain variable region and heavy chain variable region from an antibody, and wherein the antigen binding protein specifically binds with a KD ≤100 nM to an epitope formed from amino acids in both CRLR and RAMP1 polypeptides.
Patent NZ-627385-A (NZ)
Title: Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
Inventor: YAN XUELEI
IPC: C07D211/76
Filed: 2011-06-03
Abstract: Disclosed is the compound AMG-232 (2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid) and compositions comprising it for the treatment of cancer (particularly for hematopoietic tumors of lymphoid lineage, soft tissue sarcoma, breast cancer, glioblastoma, acute myeleogenous leukemia and melanoma). Also disclosed are synthetic intermediates useful for the preparation of AMG-232 and which include (3S,5S,6R,8S)-8-allyl-6-(3-chlorophenyl)-5-(4-chlorophenyl)-3-isopropyl-8-methyl-2,3,5,6,7,8-hexahydrooxazolo[3,2-a]pyridin-4-ium trifluoromethanesulfonate, (3S,5R,6R)-3-allyl-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyltetrahydro-2H-pyran-2-one, (5R,6R)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyltetrahydro-2H-pyran-2-one, (4R,5R)-4-(3-chlorophenyl)-5-(4-chlorophenyl)-5-hydroxy-2-methylpentanoic acid and isopropyl 4-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-5-oxopentanoate.
Patent NZ-629273-A (NZ)
Title: Compositions and methods for the treatment of infections and tumors
Inventor: SHARPE ARLENE
IPC: A61K39/00
Filed: 2007-12-26
Abstract: Disclosed is the use of activated T cells and a PD-1 antagonist in the manufacture of a medicament for inducing an immune response to a tumor antigen of interest in a mammalian subject having a tumor for treating said tumor, wherein the T cells specifically recognize the tumor antigen of interest and wherein the tumor is a lymphoproliferative cancer. Also disclosed is the use of a Programmed Death (PD-1) antagonist and a tumor antigen or a nucleic acid encoding the tumor antigen in the manufacture of a medicament for treating a mammalian subject having lymphoproliferative cancer.
Patent NZ-630133-A (NZ)
Title: Vaccines for serogroup x meningococcus
Inventor: PIZZA MARIAGRAZIA
IPC: A61K39/095
Filed: 2013-06-14
Abstract: Disclosed is an immunogenic composition for use in vaccination of a subject against serogroup X meningococcus, wherein the composition comprises a meninigococcoal fHbp antigen and an aluminium salt adjuvant, and optionally NHBA and/or NadA antigens. The composition is either free from meningococcal outer membrane vesicles, or includes said vesicles and the fHbp antigen is soluble.